Testosterone Cypionate Hair and Skin Changes: What to Expect and How to Manage Them

How Testosterone Cypionate Affects Androgen Levels in Skin Tissue

Testosterone cypionate is an esterified androgen depot injected intramuscularly, most often at 100 to 200 mg every 7 to 14 days for male hypogonadism. After the ester is cleaved, free testosterone enters circulation and then skin tissue, where the enzyme 5-alpha-reductase type 1 (abundant in sebaceous glands) and type 2 (dominant in hair follicles) convert it to DHT. DHT binds the androgen receptor with roughly three times the affinity of testosterone itself, making it the primary mediator of cutaneous androgen effects.

The DHT Pathway and Why It Matters

Skin is not a passive recipient of circulating hormones. Sebocytes, keratinocytes, and dermal papilla cells all express androgen receptors, and local DHT production amplifies the signal far beyond what serum DHT levels alone would suggest. A 2020 review in the Journal of Investigative Dermatology confirmed that scalp sebaceous glands produce DHT intracrinologically, meaning the scalp micro-environment generates its own androgen burden independent of circulating levels (1).

Peak-and-Trough Pharmacokinetics and Skin Flares

Standard weekly injections of testosterone cypionate produce a serum peak at 24 to 72 hours post-injection and a trough near day 7. These fluctuations matter for skin. Patients frequently report acne flares in the 48 to 72-hour post-injection window, corresponding to the androgen surge. Splitting the weekly dose into twice-weekly injections (e.g., 50 mg every 3.5 days instead of 100 mg weekly) flattens the peak-to-trough ratio and is one of the most practical, underused strategies for reducing injection-related skin changes.

Baseline Sensitivity Determines Individual Risk

Two men on identical testosterone cypionate doses can have dramatically different skin outcomes. Androgen-receptor gene polymorphisms, specifically the length of the CAG repeat in exon 1, determine receptor sensitivity. Shorter CAG repeats confer higher androgen-receptor activity, meaning even modest DHT elevations produce stronger sebaceous and follicular responses. Clinicians ordering TRT should ask about personal and family history of acne and hair thinning before writing the first prescription.

Acne and Oily Skin on Testosterone Cypionate

Acne is the most frequently reported cutaneous side effect of TRT. Sebaceous gland size and sebum output are directly proportional to androgen exposure. When testosterone cypionate raises serum testosterone from hypogonadal ranges (below 300 ng/dL) to the mid-normal range (450 to 700 ng/dL), sebum production increases within weeks.

Incidence Data

In the T-Trials, a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with confirmed hypogonadism (average baseline testosterone 234 ng/dL), skin and acne changes were tracked as secondary safety endpoints. The T-Trials confirmed improvements in sexual function, vitality, and walking distance with testosterone gel, but the testosterone-treated group showed a higher rate of acne-like skin events compared with placebo (2). Real-world registry data from the European Male Ageing Study have reported acne rates of 4 to 6% in TRT users versus under 1% in age-matched controls.

Grades of Acne and Treatment Ladder

Mild comedonal acne (grade I) typically responds to topical adapalene 0.1% gel or benzoyl peroxide 2.5 to 5% wash applied daily. Moderate inflammatory acne (grade II, III) may require topical clindamycin 1% or a brief course of oral doxycycline 100 mg twice daily for 8 to 12 weeks. Severe nodulo-cystic acne on TRT is uncommon but represents a clinical decision point: the prescribing clinician should weigh dose reduction, switching to a lower-androgen formulation (testosterone gel produces smaller peak-to-trough swings than depot injections), or, in refractory cases, oral isotretinoin at 0.5 mg/kg/day.

Oily Skin Without Acne

Many patients report sebum excess without frank acne lesions. Oily skin typically begins 4 to 8 weeks after initiation and plateaus around month 3. A gentle foaming cleanser (pH 4.5 to 5.5) used twice daily, combined with niacinamide 5% serum, reduces visible sebum without stripping the barrier. If oiliness is severe, the dose-splitting strategy described above often provides noticeable relief within four to six weeks.

Testosterone Cypionate and Hair Loss: Androgenic Alopecia

Hair loss is the cutaneous change that patients worry about most, and the science is more nuanced than simple "testosterone causes baldness."

The Follicle Miniaturization Process

Androgenic alopecia (AGA) is a genetically primed, androgen-dependent process. DHT shortens the anagen (growth) phase of terminal scalp follicles and converts them to vellus-like miniaturized hairs over successive cycles. The process requires both genetic susceptibility and androgen exposure. Raising testosterone with cypionate does not cause AGA in men whose follicles lack the genetic predisposition, but it accelerates the process in men who are genetically primed. A 2019 systematic review in JAMA Dermatology found no consistent evidence that TRT initiates AGA in men with no personal or family history, but it concluded that TRT may accelerate existing AGA by several years in predisposed individuals (3).

Pattern and Timeline

Hair loss associated with TRT follows the Hamilton-Norwood pattern: bitemporal recession and crown thinning before diffuse loss. Patients genetically predisposed to AGA often notice increased shedding (telogen effluvium-like phase) 8 to 16 weeks after starting testosterone cypionate, as a cohort of follicles that were already in late anagen are pushed prematurely into catagen. This initial shedding phase can alarm patients, but it is a transitional phenomenon. Shedding that persists beyond 6 months is consistent with ongoing miniaturization and warrants intervention.

Prevention and Treatment Options

Finasteride 1 mg daily is the most evidence-supported pharmacological option. By inhibiting 5-alpha-reductase type 2, finasteride reduces scalp DHT by approximately 70% without substantially lowering serum testosterone, which means TRT efficacy is preserved. The Finasteride Study Group's key trial (N=1,553) demonstrated a 48% increase in hair count at 12 months versus placebo, with continued benefit at 5 years (4). Dutasteride 0.5 mg daily inhibits both type 1 and type 2 5-alpha-reductase, reducing scalp DHT by up to 90%, but it is used off-label for AGA and suppresses DHT more aggressively, which may reduce some TRT benefits in tissues that rely on DHT conversion.

Topical minoxidil 5% solution or 2% solution (applied twice daily) or minoxidil 5% foam (once daily) extends the anagen phase through a mechanism independent of androgen signaling, making it additive to finasteride rather than redundant. A Cochrane review of 27 randomized trials confirmed minoxidil 5% solution's superiority over 2% for hair count outcomes in men (5). Low-level laser therapy (LLLT) devices cleared by FDA at 650 nm wavelength, used three times weekly, showed statistically significant terminal hair count increases in a 26-week randomized trial (N=110, P<0.001) (6).

Body Hair and Beard Growth Changes

Testosterone cypionate can increase terminal hair density on the chest, abdomen, back, and face. Unlike scalp follicles, body and beard follicles are stimulated rather than miniaturized by DHT. This paradox (same hormone, opposite effects depending on follicle location) is explained by differences in androgen receptor expression, co-regulator proteins, and paracrine signaling in the dermal papilla.

Expected Timeline and Magnitude

Body hair increases become noticeable at 3 to 6 months and may continue for 2 to 3 years before plateauing. Beard density changes follow a similar timeline. Men with lower baseline testosterone who achieve eugonadal levels on TRT often report the most dramatic body hair increases. This is not a side effect requiring treatment in most cases, but patients should be counseled to expect it.

Trans Men on Testosterone Cypionate

Transgender men using testosterone cypionate for gender-affirming hormone therapy experience virilization including facial hair growth, increased body hair, and male-pattern scalp hair changes. The Endocrine Society's 2017 clinical practice guidelines for transgender care note that body and facial hair growth may require 3 to 5 years to reach maximal effect, and that scalp hair thinning follows the same DHT-dependent mechanism as in cisgender men (7). The same preventive strategies (finasteride, minoxidil) apply, but some transgender men prefer to delay or forgo them given the desired virilizing goals.

Injection-Site Skin Reactions

Testosterone cypionate is dissolved in cottonseed oil or sesame oil and injected into the gluteal or deltoid muscle. Local skin and subcutaneous tissue reactions occur in a meaningful subset of patients.

Types of Reactions

Erythema, induration, and tenderness at the injection site are the most common reactions, reported in up to 6.6% of patients in post-marketing surveillance data compiled by FDA (8). These reactions are usually self-limited and resolve within 3 to 5 days. Oil vehicle hypersensitivity (to cottonseed or sesame oil) is a less common but clinically important cause of persistent injection-site nodules. Switching to a different ester (testosterone enanthate, which uses sesame or castor oil depending on the manufacturer) can resolve the reaction if cottonseed oil is the culprit.

Subcutaneous vs. Intramuscular Delivery

Some patients and compounding pharmacies use subcutaneous injection of testosterone cypionate at smaller volumes (0.5 to 1 mL). Subcutaneous delivery produces a slower absorption profile and smaller peak-to-trough swings, which may reduce androgen-spike-related skin changes including acne. A 2017 study in the Journal of Urology (N=400) found subcutaneous testosterone cypionate achieved comparable serum testosterone levels to intramuscular injection with a lower incidence of injection-site reactions (9).

Polycythemia, Estradiol, and Indirect Skin Effects

Skin changes from testosterone cypionate are not limited to direct androgen signaling. Two indirect mechanisms deserve attention.

Estradiol Conversion and Skin Quality

Testosterone aromatizes to estradiol in adipose tissue. For most men, the estradiol rise from TRT remains within the normal male range (20 to 40 pg/mL) and actually contributes positively to skin hydration and collagen synthesis. Estrogen receptors in skin regulate collagen turnover; studies in postmenopausal women consistently show estrogen deficiency accelerates dermal thinning by up to 1.13% per year (10). Men who use anastrozole aggressively to suppress estradiol below 20 pg/mL may paradoxically worsen skin quality, dry skin, and joint symptoms, a point often missed in TRT management discussions.

Polycythemia and Flushing

Testosterone cypionate stimulates erythropoiesis. Hematocrit above 54% is the FDA-defined threshold for dose reduction or treatment interruption (8). Elevated hematocrit increases blood viscosity and can produce facial flushing and skin redness that patients sometimes attribute to other causes. Monitoring CBC at baseline, then at 3 months, then annually per the American Urological Association's 2022 guidelines, catches this before it becomes a safety issue (11).

Monitoring Protocol for Hair and Skin on Testosterone Cypionate

A structured monitoring approach reduces both the incidence and severity of dermatological changes. The following clinical framework reflects current evidence and HealthRX clinical practice.

Pre-Treatment Assessment

Before the first injection, document: personal history of acne (grade and prior treatments), family history of AGA (maternal and paternal lines), Fitzpatrick skin type, and baseline sebum score using a Sebumeter or clinical grading scale. Photograph the frontal hairline and crown using standardized lighting and distance. Obtain baseline serum testosterone, DHT, SHBG, hematocrit, and PSA.

First 90 Days

Re-assess skin at 6 and 12 weeks. Acne appearing at week 4 to 6 is a signal to adjust injection frequency before escalating topical treatment. If the Hamilton-Norwood grade advances by one stage within 8 weeks of initiation, introduce finasteride 1 mg daily at the 8-week visit rather than waiting.

Ongoing Annual Review

Repeat standardized scalp photography annually. Track acne grades at every visit. If hematocrit exceeds 54%, reduce the testosterone cypionate dose by 25 to 30% or extend the injection interval from 7 to 10 to 14 days before considering therapeutic phlebotomy.

Comparing Testosterone Cypionate to Other Formulations: Skin Implications

Not all testosterone delivery systems produce the same skin profile.

Gels and Transdermal Patches

Testosterone gels (AndroGel 1.62%, Testim 1%) applied daily to skin produce smoother serum profiles with lower peak testosterone levels than weekly IM injections. The T-Trials used testosterone gel 1% at doses titrated to achieve mid-normal serum levels. The flatter pharmacokinetic profile translates to less acne in most patients. A head-to-head analysis within the T-Trials database found skin-related adverse events were numerically lower with gel than with injectable formulations, though the trial was not powered for this comparison (2).

The Endocrine Society's 2018 clinical practice guideline for male hypogonadism states: "Clinicians should consider that injectable testosterone preparations produce supraphysiologic testosterone peaks, which may increase certain side effects compared with transdermal preparations" (12).

Testosterone Pellets

Subcutaneous pellet implants (Testopel, 75 mg per pellet, typically 6 to 12 pellets per insertion) release testosterone slowly over 3 to 6 months with very flat pharmacokinetics. Acne rates with pellet therapy appear lower than with injectable cypionate in retrospective clinic audits, though head-to-head randomized data are absent. The trade-off is that dose adjustment requires a new procedure.

Practical Patient Counseling Points

Patients starting testosterone cypionate need clear, specific guidance rather than generic warnings.

Acne prevention starts before the first injection: begin twice-daily gentle cleanser and daily niacinamide 4 to 5% serum one week before. Men with even mild family history of AGA should have a conversation about finasteride at the prescribing visit, not after they notice hair loss. Scalp hair loss from follicle miniaturization does not grow back reliably once established; prevention is consistently more effective than reversal.

Dose-splitting to twice-weekly injections costs nothing and reduces the androgen spike more effectively than any topical product. Body hair increase is expected and does not require treatment. Patients should know that the same dose that grows chest hair may thin scalp hair, and this is a pharmacological property of the drug, not a dosing error.

Any injection-site nodule persisting beyond two weeks warrants evaluation for oil-vehicle hypersensitivity or sterile abscess. Switching the vehicle oil resolves most cases without abandoning TRT.

The Endocrine Society's guideline authors conclude: "Monitoring for polycythemia, acne, and changes in prostate-specific antigen is required at 3 and 6 months after initiating testosterone therapy, and annually thereafter" (12).

Serum DHT measurement at the 8-week follow-up visit provides actionable data. A DHT above 95 ng/dL (the upper end of the adult male reference range) in a patient already reporting scalp shedding is a clear indication to initiate finasteride 1 mg daily without further delay.